Press Room

IRDD 2021 - The BioTech Pharma Summit

Start
Monday, November 29, 2021 - 00:00
End
Tuesday, November 30, 2021 - 00:00
Location: Porto, Portugal
BioTech Pharma Summit Hovione is present with a Drug Product Development Scientist | Hovione

Hovione is present at the BioTech Pharma Summit taking place in Oporto, Portugal. Our expert in drug product develpment will present on day 1 in the Inhalation & Respiratory Drug Delivery stream. Join us.

 

Hovione Presentation

Day 1 - Monday, November 29th 2021 | 11:30 - 12:00
Stream: Inhalation & Respiratory Drug Delivery
Session: Inhalation Formulation Solutions & Technology

 

High Dosage DPI – formulation and process development considerations

Presenter: Beatriz Noriega Fernandes, Scientist, Formulation Group - Drug Product Development at Hovione

Abstract: 
Biopharmaceuticals represent the most promising and fastest growing field in the pharmaceutical area. These therapeutics show very high specificity and potency at relatively low concentrations and enable the treatment of otherwise untreatable diseases. One of the main challenges when developing a spray dried biopharmaceutical formulation for Dry Powder Inhalers is the generation of a stable aerosol able to reach the lungs while preserving the integrity of the biopharmaceutical, rendering it safe and effective. In this presentation the most promising alternatives to freeze drying with focus on particle engineering methods for dry powder inhalation such as spray drying will be discussed. Case-studies will be provided to support participants diving into specific examples of selected topics.
The presentation will provide participants the opportunity to learn about the integration of technologies and capabilities to take a Dry Powder Inhalation product development from early-stage development to commercial stage products.

 

 

Hovione present at the BioTech Pharma Conference | Hovione Virtual Stand

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Our team will be pleased to meet you.

 

Schedule a meeting button | Hovione

 

 

You might be interested in:

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025